|Cover Image Credit: Duke University Twitter|
Poliovirus May Be Effective In Prolonging Life In Those Diagnosed With Most Common Form OF Brain Cancer
New research demonstrates that the polio virus might be viable in extending life in those diagnosed with glioblastoma, which is the deadliest kind of brain tumor.
Glioblastoma is the most common and aggressive cancerous brain tumor in grown-ups.
Dr. Steven Toms, a neurosurgeon at Rhode Island Hospital and the executive of the Brain Tumor Program, clarifies why it’s so fatal, with a normal future of two years.
“No matter what I do there’s always some of the tumor left behind. Even when the MRI looks perfect, there are many hundreds of thousands, if not millions of tumor cells left behind,” said Dr. Toms.
“Glioblastomas are extremely hard to treat tumors,” said Dr. Alexander Mohler, a neuro-oncologist at Lifespan Cancer Institute.
He says chemotherapy and radiation have helped, yet new research out of Duke University proposes the poliovirus, joined with the regular cold virus, may help extend life in a few patients.
“I’ve been doing this for 50 years and I’ve never seen results like this,” Dr. Darell Bigner, the director emeritus of The Preston Robert Tisch Brain Tumor Center at the Duke Cancer Institute, who is helping develop the treatment, told NPR.
— Duke University (@DukeU) June 29, 2018
“It’s administered via what’s known as a convection enhanced delivery so basically they put a tube in the tumor and administer the drug,” said Mohler.
“What we’re trying to do here is to hijack the body’s own immune system so all of us, or just about all of us, have had our polio virus vaccines,” said Toms.
Toms says everybody has been exposed to the cold virus.
“Thus, what the Duke program is attempting to do is to hijack the ability of the body to recognize some of the proteins out of the poliovirus and the rhino virus to a sort of light a fire under our immune system and say ‘hey guys, come here, let’s attack the glioblastoma cells where these viruses are being expressed after they were put in to the brain,” said Toms
This treatment came with a few risks. A few patients had reactions like seizures, headaches and discourse issues. In a few occurrences, there could be inflammation in the brain.
As indicated by the outcomes from the clinical trial, among 61 patients with repetitive glioblastoma who got the trial treatment, 21 percent will survive for three years or longer, compared with just 4 percent of those treated with chemotherapy, the present standard treatment, CNN reported.
There are different immunotherapies under survey, and something many refer to as tumor treatment field treatment. The patient wears a cap with four sets of electrodes.
Those electrodes meddle with cancer cells when they’re attempting to gap and spread.
“I, personally have a couple of patients who are beyond 8 years right now with that treatment with no sign of disease,” said Toms.
To read more about glioblastoma, click here.